Treatment Options for Anemia in Kidney Transplant Patients: A Review
Anemia is common after kidney transplantation. The etiology may be multifactorial, such as causes of anemia in the general population and causes that are unique to the kidney transplant setting. Posttransplant anemia, particularly when severe, may be associated with adverse effects such as graft fai...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-08-01
|
| Series: | Kidney Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059523000973 |
| _version_ | 1827874810109100032 |
|---|---|
| author | Mario Bonomini Lorenzo Di Liberato Vittorio Sirolli |
| author_facet | Mario Bonomini Lorenzo Di Liberato Vittorio Sirolli |
| author_sort | Mario Bonomini |
| collection | DOAJ |
| description | Anemia is common after kidney transplantation. The etiology may be multifactorial, such as causes of anemia in the general population and causes that are unique to the kidney transplant setting. Posttransplant anemia, particularly when severe, may be associated with adverse effects such as graft failure, mortality, and a decline in kidney function. After careful investigation, that is, having excluded or treated reversible causes of anemia, treatment of anemia in patients with a kidney transplant is based on iron supplementation or erythropoiesis-stimulating agents (ESA), although there are no specific guidelines on anemia management in this patient population. Iron therapy is often needed, but optimal and safe iron-deficiency management strategies remain to be defined. Evidence suggests that ESAs are safe and potentially associated with favorable outcomes. Better graft function has been reported with ESA use targeting hemoglobin levels higher than those recommended in the general population with chronic kidney disease and with no apparent increased risk of cardiovascular events. These results require further investigation. Data on the use of hypoxia-inducible factor inhibitors are limited. Prevention and treatment of anemia in kidney transplantation can improve patients’ quality of life, life expectancy, allograft function, and survival. |
| first_indexed | 2024-03-12T16:57:11Z |
| format | Article |
| id | doaj.art-d9051a91d7fe42968ca0880b99d58bed |
| institution | Directory Open Access Journal |
| issn | 2590-0595 |
| language | English |
| last_indexed | 2024-03-12T16:57:11Z |
| publishDate | 2023-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney Medicine |
| spelling | doaj.art-d9051a91d7fe42968ca0880b99d58bed2023-08-08T04:05:53ZengElsevierKidney Medicine2590-05952023-08-0158100681Treatment Options for Anemia in Kidney Transplant Patients: A ReviewMario Bonomini0Lorenzo Di Liberato1Vittorio Sirolli2Address for Correspondence: Dr Mario Bonomini, MD, Nephrology and Dialysis Unit, SS. Annunziata Hospital, Via dei Vestini66100 Chieti, Italy.; Nephrology and Dialysis Unit, Department of Medicine, G. d’Annunzio University, SS. Annunziata Hospital, Chieti, ItalyNephrology and Dialysis Unit, Department of Medicine, G. d’Annunzio University, SS. Annunziata Hospital, Chieti, ItalyNephrology and Dialysis Unit, Department of Medicine, G. d’Annunzio University, SS. Annunziata Hospital, Chieti, ItalyAnemia is common after kidney transplantation. The etiology may be multifactorial, such as causes of anemia in the general population and causes that are unique to the kidney transplant setting. Posttransplant anemia, particularly when severe, may be associated with adverse effects such as graft failure, mortality, and a decline in kidney function. After careful investigation, that is, having excluded or treated reversible causes of anemia, treatment of anemia in patients with a kidney transplant is based on iron supplementation or erythropoiesis-stimulating agents (ESA), although there are no specific guidelines on anemia management in this patient population. Iron therapy is often needed, but optimal and safe iron-deficiency management strategies remain to be defined. Evidence suggests that ESAs are safe and potentially associated with favorable outcomes. Better graft function has been reported with ESA use targeting hemoglobin levels higher than those recommended in the general population with chronic kidney disease and with no apparent increased risk of cardiovascular events. These results require further investigation. Data on the use of hypoxia-inducible factor inhibitors are limited. Prevention and treatment of anemia in kidney transplantation can improve patients’ quality of life, life expectancy, allograft function, and survival.http://www.sciencedirect.com/science/article/pii/S2590059523000973Anemiakidney transplantationironerythropoiesis-stimulating agentgraft failureHIF inhibitors |
| spellingShingle | Mario Bonomini Lorenzo Di Liberato Vittorio Sirolli Treatment Options for Anemia in Kidney Transplant Patients: A Review Kidney Medicine Anemia kidney transplantation iron erythropoiesis-stimulating agent graft failure HIF inhibitors |
| title | Treatment Options for Anemia in Kidney Transplant Patients: A Review |
| title_full | Treatment Options for Anemia in Kidney Transplant Patients: A Review |
| title_fullStr | Treatment Options for Anemia in Kidney Transplant Patients: A Review |
| title_full_unstemmed | Treatment Options for Anemia in Kidney Transplant Patients: A Review |
| title_short | Treatment Options for Anemia in Kidney Transplant Patients: A Review |
| title_sort | treatment options for anemia in kidney transplant patients a review |
| topic | Anemia kidney transplantation iron erythropoiesis-stimulating agent graft failure HIF inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S2590059523000973 |
| work_keys_str_mv | AT mariobonomini treatmentoptionsforanemiainkidneytransplantpatientsareview AT lorenzodiliberato treatmentoptionsforanemiainkidneytransplantpatientsareview AT vittoriosirolli treatmentoptionsforanemiainkidneytransplantpatientsareview |